PFU (EMEA) Limited, a Fujitsu company, has registered almost 400 new partners in the region within the last 12 months. Offering partners the support they need to effectively sell and incorporate marketing leading image capture devices into their solutions to end customers, PFU EMEA’s Imaging Channel Program boasts quick and easy access to the content that matters to the channel, as well as a compelling loyalty scheme.
Of the 396 companies who joined the Imaging Channel Program since April 2018, 77 were in the UK, and able to begin building PFU EMEA’s solutions into their services.
The Imaging Channel Program, which was launched in April 2016, provides partners with all the collateral they need to support their sales funnel, including marketing material, offers and, training services. PFU EMEA also offers a loyalty program, Imaging Rewards, which gives partners recognition for their engagement, commitment and, sales. Rewards include business building services, travel, and the latest consumer electronics and experiences. Its widespread availability across 59 countries in EMEA means two-thirds of all new enrolments in the Imaging Channel Program also participate in Imaging Rewards.
Neil Walker, Senior Manager, Channel Marketing, PFU (EMEA) Limited said, “the channel is and continues to be our core distribution mechanism in EMEA, and we’re excited to see new partners across the region recognise our market leading solutions. With organisations increasingly seeking solutions that will enable them to undertake digital transformation projects, it’s important that their providers can rely on their vendor partners to provide them with best-in-class solutions and all the supporting material they need, as well as recognising and rewarding them for their continuing commitment and loyalty.”
In November 2018 PFU EMEA also launched Japan II, a competition specifically for its partners, which offers the chance to win a trip to Japan and visit PFU’s head office. To have a chance of winning, entrants need to register their sales secured between November 2018 and the end of March 2019.